D. Boral Capital Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $10.00 target price on the stock. D. Boral Capital’s price target would indicate a potential upside of 224.68% from the company’s previous close.

A number of other research firms also recently commented on ANIX. Maxim Group initiated coverage on Anixa Biosciences in a research note on Friday, March 21st. They issued a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday.

Anixa Biosciences Stock Performance

Shares of ANIX opened at $3.08 on Wednesday. Anixa Biosciences has a one year low of $2.07 and a one year high of $4.20. The stock’s fifty day moving average is $2.96 and its 200-day moving average is $3.01. The firm has a market capitalization of $99.17 million, a price-to-earnings ratio of -7.90 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). Analysts forecast that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Activity

In related news, CEO Amit Kumar purchased 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average cost of $2.23 per share, for a total transaction of $95,890.00. Following the acquisition, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lewis H. Titterton, Jr. purchased 10,000 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were acquired at an average price of $2.57 per share, for a total transaction of $25,700.00. Following the purchase, the director now owns 922,334 shares in the company, valued at $2,370,398.38. The trade was a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 75,289 shares of company stock worth $177,021 over the last quarter. Corporate insiders own 25.30% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in Anixa Biosciences during the 3rd quarter valued at approximately $34,000. Westside Investment Management Inc. lifted its holdings in shares of Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after buying an additional 21,100 shares during the last quarter. Prosperity Wealth Management Inc. bought a new stake in shares of Anixa Biosciences in the fourth quarter valued at approximately $54,000. Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the fourth quarter worth $26,000. Finally, Jane Street Group LLC bought a new position in Anixa Biosciences during the fourth quarter worth $67,000. Institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.